查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1837436

肝肾综合症治疗市场（按产品类型、给药途径、患者严重程度和最终用户划分）—2025-2032 年全球预测

Hepatorenal Syndrome Treatment Market by Product Type, Route Of Administration, Patient Severity, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，肝肾症候群治疗市场将成长至 74.5 亿美元，复合年增长率为 5.64%。

主要市场统计数据
基准年2024年 48亿美元
预计2025年 50.7亿美元
预测年份：2032年 74.5亿美元
复合年增长率（%） 5.64%

简明的策略入门指南，概述了当今肝肾症候群治疗的临床复杂性、相关人员的优先事项和决策要求

肝肾症候群是一种复杂的疾病，其特征是肝功能衰竭和进行性性肾功能障碍相互作用，需要临床、付款方和商业层面的协调应对。本执行摘要旨在提供一份简明的策略性入门指南，综合当今影响治疗方法的临床进展、治疗定位和商业性需求。本摘要重点在于影响临床决策和相关人员奖励的驱动因素，旨在为高阶主管提供做出明智投资和合作决策所需的背景资讯。

随着多学科团队努力在短期肾臟支持和长期肝臟稳定之间取得平衡，肝肾症候群的临床管理也不断演变。除了程序性介入之外，人们重新关注调节肾臟灌注和全身性血流动力学的药物策略。因此，临床医生、健康系统和专科组织正在重新调整患者治疗路径，优先考虑早期发现和分层治疗，而支付方也在重新评估覆盖框架，以反映临床效益和资源利用率。本介绍对这种转变模式进行了更深入的分析，并为产业领导者提供了行动建议。

新的临床分层、现代化的医疗保健服务和价值主导的奖励正在重塑肝肾综合征的治疗决策途径

由于临床创新、医疗服务模式的变革以及监管预期的不断变化，肝肾症候群的治疗格局正在发生重大变化。近期的临床实务使得患者分层更加精细，因此可以采取差异化的治疗途径，而非千篇一律的治疗方案。同时，支持性治疗和血流动力学管理的进展正在改变患者的短期预后，并促使临床医生重新考虑何时以及如何实施疾病修正治疗。

随着临床治疗的不断发展，支付模式和医院营运重点也在奖励基于价值的医疗服务，这种服务强调展示临床效用、缩短住院时间和降低再入院率。製剂和给药途径的创新使得该服务在从重症住院治疗到门诊和居家护理等各种医疗环境中得到更广泛的应用。这些变化共同为研发者、医疗服务提供者和支付方创造了机会，也赋予了他们义务，促使他们合作制定证据生成和实施策略，将临床潜力转化为患者和医疗系统的可衡量效益。

贸易政策和关税的变化正在推动整个肝肾综合征治疗价值链的策略性供应链调整和采购弹性措施。

近期政策週期中推出的新关税政策和贸易措施，为透过国际供应链采购活性成分、製剂和成品的企业带来了策略上的复杂性。依赖跨境采购的企业被迫实现供应商、库存策略和定价的多元化，以减轻进口成本上涨的影响。为此，一些企业加快了近岸外包或合格的替代供应商，以保持供应的连续性和利润的稳定性。

监管和清关程序也已成为上市时间和分销规划中更关键的因素。因此，商业化时间表现在通常包含关税情境分析和应急计划，以确保关键市场的产品供应。营运团队优先考虑合约弹性和包含风险共担框架的长期供应商关係。这些调整也对采购、法务和商务部门产生了广泛的影响，这些部门必须紧密合作，在保障财务表现的同时，维持治疗药物的可预测性。

策略性地调整产品定位、交付形式、患者风险状况和护理环境，以优化肝病治疗的临床应用和商业性影响

細項分析揭示了产品类型、给药途径、患者病情和最终用户环境等方面的不同策略考量，这些因素会影响临床定位和商业性执行。透过产品类型区分品牌学名药，我们发现品牌药往往注重临床差异化、临床试验证据和溢价策略，而学名药主要在成本和可及性方面展开竞争，从而影响处方动态和处方行为。就给药途径而言，静脉注射的区别决定了操作流程，静脉注射通常更适合急性住院患者，而口服给药则更适合门诊病人管理，甚至可能居家照护。

I 型和 II 型患者的病情严重程度细分需要临床方案和价值叙述的协调，因为 I 型患者通常需要更密集的干预和快速的血流动力学稳定，而 II 型患者可能受益于更长期的优化策略。最后，居家医疗机构、医院和专科诊所的终端使用者细分直接影响分销、病患监测要求和支援服务。这些细分维度相互影响，形成奖励，决定了临床采用模式、相关人员以及製造商和服务供应商在其上市计划中必须考虑的商业性优先事项。

协调的区域策略和本地证据产生对于应对全球监管多样性、报销差异和采用途径至关重要

区域动态对药品法规、报销模式、临床实践和供应链有着重大影响，因此了解这些差异对于制定市场准入和商业化策略至关重要。在美洲，临床研究环境和支付系统差异巨大，需要製定细緻入微的合作计划，以应对公共和私人承保流程，并优先考虑真实世界证据的生成，以支持处方可及性。在欧洲、中东和非洲，监管协调工作与国家层面的显着差异并存，许可策略和卫生技术评估应用必须根据该地区的证据和经济阈值进行客製化。

在亚太地区，创新医疗模式正在一些市场迅速普及，但由于各国基础设施和采购惯例的巨大差异，这一进程并不均衡。与区域利害关係人建立策略相关人员伙伴关係并投资于当地临床教育，可以在产能允许的情况下加速采用；而在其他地区，成本敏感的采购环境则需要采取其他可及策略。为了确保患者在不同地区永续获得医疗服务，製造商应根据当地的医疗实践模式和报销情况，量身定制临床开发、定价和分销计划。

竞争差异化源自于基于临床证据的肝病治疗策略、製造敏捷性以及促进采用和可扩展性的伙伴关係模式

肝肾综合征治疗生态系统中的关键参与者在战略重点上各不相同，从专注于新型血流动力学和肾灌注药物的开发商，到优化製剂和给药平台以提高整个治疗领域可用性的公司。一些公司透过有针对性的临床计画和真实世界试验来强调临床差异化，而另一些公司则透过注重成本效益的生产和供应链弹性来优先考虑广泛的可及性。专科药物开发商、契约製造和医疗保健提供者之间的合作对于缩短开发週期并确保肠外和口服製剂生产的可扩展性变得越来越重要。

策略联盟和授权协议是扩大地域覆盖范围和共用开发风险的常见手段。积极投资核准后观察性研究和与专业协会合作的教育计画的公司，能够影响临床指南和处方实践。此外，将患者支援服务和数位监控功能整合到产品中的公司，可以透过提高依从性并促进住院和门诊护理的连续性，提供差异化的价值提案。

透过以证据为导向的开发、供应链应急计画和分段商业化策略，提供以行动为导向的指导，以加速采用和復原能力

为了抓住肝肾综合征治疗领域的机会，产业领导者应优先考虑一种整合方法，将临床证据产生、供应链韧性和相关人员参与相结合。首先，临床开发应优先考虑能引起临床医生、付款方和监管机构共鸣的终点，以促进更快的采用和报销讨论。这包括设计反映真实世界治疗途径的实用性试验，并展示对医疗保健系统重要的结果，例如降低加护病房的使用率和改善肾功能轨迹。

其次，供应链和筹资策略应针对地缘政治和关税相关情境进行压力测试，并制定针对替代供应商、近岸外包选项和库存缓衝的应急计画。第三，商业策略应反映细分市场的优先事项，例如协调品牌和非专利的定位，突显相关静脉注射或口服製剂的营运优势，并满足I类和II类患者群体的不同需求。最后，与医院、专科诊所和居家照护机构建立伙伴关係，并整合支援服务和数位监控，可以提高护理的依从性和连续性，从而强化支付方和提供者双方的价值提案。

结合临床医师意见、监管调查和供应链访谈的严格、多源质性调查方法，为相关人员提供可行的策略见解

本分析所采用的调查方法结合了跨部门证据综合分析，旨在捕捉临床实务、相关人员和营运现状的变化​​。主要资讯包括奖励执业肝病专家、肾臟科医师、医院药师和专科诊所管理人员，以检验实际的实务途径和应用障碍。补充资讯包括对同侪审查临床文献、临床试验註册中心和监管指导文件的系统性综述，以检验治疗趋势和不断发展的护理标准。

营运洞察源自于对供应链和采购专家的访谈，以及对已发布的政策公告和贸易指南的审查，旨在了解关税和采购变化的影响。在适当的情况下，调查方法着重于质性综合和情境分析而非定量预测，以确保研究结果适用于不同的市场环境。调查团队也进行了严格的资讯来源检验和相关人员交叉核对，以确保可行的洞察能够反映当前的临床和商业现实。

结论摘要强调了综合证据、营运弹性和有针对性的参与，以将临床进展转化为永续的患者可及性

总而言之，有效驾驭肝肾综合症治疗格局需要整合策略，将临床差异化、营运韧性和市场导向的参与度相结合。临床进展和不断发展的护理模式为改善患者预后提供了机会，但要实现这些益处，需要製定与临床医生和付款人沟通的循证策略，以及确保药物可及性连续性的供应链决策。能够预见区域和政策差异的公司将能够更好地制定符合当地实践和报销现实的、具有韧性的商业化计划。

要从洞察转化为影响力，需要对有针对性的临床计画进行重点投资，与医院和门诊机构的医疗服务提供者合作，并积极主动地管理采购风险。透过强调可衡量的临床效益以及切实可行的应用考量，相关人员可以建立一个令人信服的价值提案，以支持永续的可及性，并最终改善肝肾症候群患者的照护途径。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 肝肾症候群早期检测的非侵入性生物标记研究进展
  • 特利加压素在改善进行性肝肾症候群患者存活率的新作用
  • 整合人工智慧演算法预测肝肾症候群的发病及结局
  • 选择性内皮素受体拮抗剂治疗HRS肾功能不全的临床评价
  • 越来越多地采用白蛋白输注通讯协定来预防肝硬化相关腹水穿刺术中的肾衰竭
  • 扩大血管加压药物治疗第1型肝肾症候群的真实世界证据研究
  • 肝肾疾病患者肾臟血流动力学监测的超音波创新
  • 不断变化的监管格局和新型 HRS 疗法的快速核准途径推动了市场发展势头

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章肝肾综合症治疗市场（依产品类型）

  • 品牌
  • 非专利的

9. 肝肾综合症治疗市场（依给药途径）

  • 静脉
  • 口服

第 10 章肝肾症候群治疗市场（依患者严重程度）

  • I型
  • II型

第11章肝肾症候群治疗市场（依最终用户）

  • 居家照护环境
  • 医院
  • 专科诊所

第十二章肝肾症候群治疗市场：按地区

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章肝肾症候群治疗市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章肝肾症候群治疗市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Mallinckrodt Pharmaceuticals plc
    • Ferring Pharmaceuticals A/S
    • Baxter International Inc.
    • Grifols, SA
    • Octapharma AG
    • CSL Limited
    • Kedrion SpA
    • LFB Group
    • B. Braun Melsungen AG
    • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-035DA3C63700

The Hepatorenal Syndrome Treatment Market is projected to grow by USD 7.45 billion at a CAGR of 5.64% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.80 billion
Estimated Year [2025] USD 5.07 billion
Forecast Year [2032] USD 7.45 billion
CAGR (%) 5.64%

A concise strategic primer outlining clinical complexities, stakeholder priorities, and decision-making imperatives shaping hepatorenal syndrome treatment today

Hepatorenal syndrome presents a complex intersection of hepatic failure and progressive renal dysfunction that demands coordinated clinical, payer, and commercial responses. The intent of this executive summary is to provide a concise, strategic primer that synthesizes clinical advances, therapeutic positioning, and commercial imperatives influencing treatment approaches today. By focusing on drivers that shape clinical decision-making and stakeholder incentives, the narrative aims to equip executives with the context required to make informed investments and partnership decisions.

Clinical management of hepatorenal syndrome continues to evolve as multidisciplinary teams strive to balance short-term renal support with long-term hepatic stabilization. Beyond procedural interventions, pharmacologic strategies that modulate renal perfusion and systemic hemodynamics are receiving renewed attention. Consequently, clinicians, health systems, and specialty providers are recalibrating patient pathways to prioritize early detection and stratified treatment, and payers are reassessing coverage frameworks to reflect both clinical benefit and resource utilization. This introduction sets the stage for a deeper analysis of shifting paradigms and recommended actions for industry leaders.

Emerging clinical stratification, care delivery modernization, and value-driven incentives are reshaping therapeutic decision pathways for hepatorenal syndrome

The landscape of hepatorenal syndrome treatment is undergoing transformative shifts driven by clinical innovation, changes in care delivery, and evolving regulatory expectations. Recent clinical practice has moved toward more nuanced patient stratification, which enables differentiated therapeutic pathways rather than a one-size-fits-all approach. At the same time, advances in supportive care and hemodynamic management have altered short-term outcomes, prompting clinicians to reassess when and how to deploy disease-modifying therapies.

Parallel to clinical evolution, payment models and hospital operational priorities are incentivizing value-based care, which places a premium on demonstrable clinical benefit, reduced length of stay, and fewer readmissions. Innovations in formulations and routes of administration are enabling broader applicability across care settings, from intensive inpatient care to outpatient and home-based options. Taken together, these shifts create both opportunities and responsibilities for developers, providers, and payers to collaborate on evidence generation and implementation strategies that translate clinical promise into measurable patient and system benefit.

Trade policy shifts and tariff changes are prompting strategic supply chain realignment and procurement resilience measures across the hepatorenal syndrome treatment value chain

The introduction of new tariff policies and trade measures in recent policy cycles has introduced a strategic layer of complexity for companies that source active ingredients, formulations, and finished products through international supply chains. Firms that depend on cross-border procurement have been compelled to reassess supplier diversification, inventory strategies, and pricing structures to mitigate the impact of increased import costs. In response, some organizations have accelerated nearshoring initiatives or qualified alternative suppliers to preserve continuity of supply and margin stability.

Regulatory compliance and customs processes have also become a more prominent factor in launch timing and distribution planning. As a result, commercialization timelines now routinely integrate tariff scenario analyses and contingency plans to ensure product availability in key markets. Operational teams are prioritizing contractual flexibility and longer-term supplier relationships that incorporate shared risk frameworks. These adjustments have broader implications for procurement, legal, and commercial functions, which must coordinate closely to maintain predictable access to therapies while protecting financial performance.

Strategically aligning product positioning, delivery modality, patient risk profiles, and care settings to optimize clinical adoption and commercial impact in hepatorenal therapy

Segmentation analysis reveals distinct strategic considerations across product type, route of administration, patient severity, and end-user settings that influence clinical positioning and commercial execution. When differentiating by product type between branded and generic options, branded therapies tend to focus on clinical differentiation, targeted clinical trial evidence, and premium pricing strategies, whereas generic entrants compete primarily on cost and accessibility, influencing formulary dynamics and prescribing behavior. Considering route of administration, the distinction between intravenous and oral delivery shapes operational workflows, with intravenous therapies typically favored in acute inpatient settings and oral options enabling outpatient management and potential home-based care pathways.

Patient severity segmentation between Type I and Type II patients necessitates tailored clinical protocols and value narratives, as Type I patients often require more intensive intervention and rapid hemodynamic stabilization, whereas Type II patients may benefit from longer-term optimization strategies. Finally, end-user segmentation across home care settings, hospitals, and specialty clinics directly affects distribution, patient monitoring requirements, and support services. Each of these segmentation dimensions interacts, creating combinations that determine clinical adoption patterns, stakeholder incentives, and commercial priorities that manufacturers and service providers must address in their go-to-market planning.

Calibrated regional strategies and localized evidence generation are essential to navigate regulatory diversity, reimbursement variability, and adoption pathways globally

Regional dynamics exert a powerful influence on regulatory pathways, reimbursement models, clinical practice, and supply chain considerations, and understanding these variations is essential for tailoring market entry and commercialization strategies. In the Americas, clinical research environments and payer systems vary widely, requiring nuanced engagement plans that address both public and private coverage processes and prioritize real-world evidence generation to support formulary access. Across Europe, Middle East & Africa, regulatory harmonization efforts coexist with significant country-level heterogeneity, which means licensing strategies and health technology assessment submissions must be customized to local evidentiary and economic thresholds.

In the Asia-Pacific region, rapid adoption of innovative care models in some markets is balanced by significant differences in infrastructure and procurement practices across countries. Strategic partnerships with regional stakeholders and investments in local clinical education can accelerate adoption where capacity allows, while cost-sensitive procurement environments necessitate alternative access strategies in other jurisdictions. Across all regions, manufacturers should calibrate their clinical development, pricing, and distribution plans to reflect local practice patterns and reimbursement realities to ensure sustainable patient access.

Competitive differentiation emerges through clinical evidence strategies, manufacturing agility, and partnership models that drive adoption and scalability in hepatorenal treatments

Key companies operating in the hepatorenal syndrome treatment ecosystem vary in their strategic focus, ranging from developers concentrating on novel hemodynamic modulators and renal perfusion agents to firms optimizing formulations and delivery platforms that improve usability across care settings. Some organizations emphasize clinical differentiation through targeted clinical programs and real-world studies, while others prioritize broad access by focusing on cost-efficient manufacturing and supply chain resilience. Collaboration between specialty pharmaceutical developers, contract manufacturers, and providers has become increasingly important to accelerate development timelines and ensure scalability of manufacturing for parenteral and oral formulations.

Strategic alliances and licensing agreements are common pathways to expand geographic reach and share development risk. Companies that proactively invest in post-approval observational studies and educational initiatives with specialist societies are better positioned to influence clinical guidelines and prescribing practices. Moreover, firms that integrate patient support services and digital monitoring capabilities into their offerings can create differentiated value propositions by improving adherence and facilitating care continuity across inpatient and outpatient settings.

Action-oriented guidance to drive adoption and resilience through evidence-focused development, supply chain contingency planning, and segmented commercialization strategies

Industry leaders should prioritize an integrated approach that combines clinical evidence generation, supply chain resilience, and targeted stakeholder engagement to capture opportunities in hepatorenal syndrome treatment. First, aligning clinical development with endpoints that resonate with clinicians, payers, and regulatory bodies will facilitate faster uptake and reimbursement discussions. This includes designing pragmatic studies that reflect real-world care pathways and demonstrating outcomes that matter to health systems, such as reductions in intensive care utilization and improvements in renal function trajectories.

Second, supply chain and procurement strategies must be stress-tested against geopolitical and tariff-related scenarios, with contingency plans for alternative suppliers, nearshoring options, and inventory buffers. Third, commercial strategies should reflect segmentation priorities by tailoring messaging for branded versus generic positioning, emphasizing the operational advantages of intravenous or oral formulations as relevant, and addressing distinct needs of Type I and Type II patient cohorts. Finally, cultivating partnerships with hospitals, specialty clinics, and home care providers to embed support services and digital monitoring will enhance adherence and continuity of care, strengthening value propositions for payers and providers alike.

A rigorous multi-source qualitative methodology combining clinician input, regulatory review, and supply chain interviews to generate actionable strategic insights for stakeholders

The research methodology underpinning this analysis integrated a cross-functional evidence synthesis designed to capture clinical practice changes, stakeholder incentives, and operational realities. Primary inputs included consultations with practicing hepatologists, nephrologists, hospital pharmacists, and specialty clinic administrators to validate real-world pathways and adoption barriers. Supplementary inputs involved systematic reviews of peer-reviewed clinical literature, clinical trial registries, and regulatory guidance documents to triangulate therapeutic trends and evolving standards of care.

Operational insights were derived from interviews with supply chain and procurement professionals, as well as reviews of publicly available policy announcements and trade guidance to understand the implications of tariff and sourcing shifts. Where appropriate, the methodology emphasized qualitative synthesis and scenario analysis over quantitative forecasting to ensure the findings remain applicable across diverse market contexts. Throughout, the research team applied rigorous source validation and cross-stakeholder corroboration to ensure that insights are both actionable and reflective of current clinical and commercial realities.

Concluding synthesis emphasizing integrated evidence, operational resilience, and targeted engagement to convert clinical progress into sustainable patient access

In conclusion, effective navigation of the hepatorenal syndrome treatment landscape requires an integrated strategy that marries clinical differentiation with operational resilience and tailored market engagement. Clinical advances and evolving care models present opportunities to improve patient outcomes, but realizing those gains depends on deliberate evidence strategies that speak to clinicians and payers, as well as supply chain decisions that protect continuity of access. Companies that anticipate regional and policy-driven variations will be better positioned to deploy resilient commercialization plans that align with local practice and reimbursement realities.

Moving from insight to impact will require focused investment in targeted clinical programs, collaboration with care providers across hospitals and outpatient settings, and proactive management of procurement risks. By emphasizing measurable clinical benefits alongside practical adoption considerations, stakeholders can build persuasive value propositions that support sustainable access and ultimately improve care pathways for patients living with hepatorenal syndrome.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in noninvasive biomarkers for early detection of hepatorenal syndrome
  • 5.2. Emerging role of terlipressin in improving survival rates among advanced hepatorenal syndrome patients
  • 5.3. Integration of artificial intelligence algorithms in predicting hepatorenal syndrome onset and outcomes
  • 5.4. Clinical evaluation of selective endothelin receptor antagonists for managing renal dysfunction in HRS
  • 5.5. Growing adoption of albumin infusion protocols to prevent renal failure in cirrhosis related paracentesis
  • 5.6. Expansion of real world evidence studies on vasoconstrictor therapies in type 1 hepatorenal syndrome
  • 5.7. Innovations in point of care ultrasonography for monitoring renal hemodynamics in hepatorenal patients
  • 5.8. Regulatory landscape shifts and expedited approval pathways for novel HRS therapies boosting market momentum

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hepatorenal Syndrome Treatment Market, by Product Type

  • 8.1. Branded
  • 8.2. Generic

9. Hepatorenal Syndrome Treatment Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral

10. Hepatorenal Syndrome Treatment Market, by Patient Severity

  • 10.1. Type I
  • 10.2. Type II

11. Hepatorenal Syndrome Treatment Market, by End User

  • 11.1. Home Care Settings
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Hepatorenal Syndrome Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Hepatorenal Syndrome Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Hepatorenal Syndrome Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Mallinckrodt Pharmaceuticals plc
    • 15.3.2. Ferring Pharmaceuticals A/S
    • 15.3.3. Baxter International Inc.
    • 15.3.4. Grifols, S.A.
    • 15.3.5. Octapharma AG
    • 15.3.6. CSL Limited
    • 15.3.7. Kedrion S.p.A.
    • 15.3.8. LFB Group
    • 15.3.9. B. Braun Melsungen AG
    • 15.3.10. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. HEPATORENAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. HEPATORENAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HEPATORENAL SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 70. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 71. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 72. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 73. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 75. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 77. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 82. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 84. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 86. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 88. NORTH AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 92. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 94. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 96. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 98. LATIN AMERICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 109. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 114. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 115. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 116. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 117. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 118. EUROPE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 124. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 126. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. MIDDLE EAST HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 134. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 135. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 136. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 137. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 138. AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 156. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 157. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 158. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 159. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. ASEAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 166. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 167. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 168. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 169. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. GCC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPEAN UNION HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 188. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 189. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. BRICS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 196. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 197. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 198. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 199. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. G7 HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 206. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 207. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 208. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 209. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. NATO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 216. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 217. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 218. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 219. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 224. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 225. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 226. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 227. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 232. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 233. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 234. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 235. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 242. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 243. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 256. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 257. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 258. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 259. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 264. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 265. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 266. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 267. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 274. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 275. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 281. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 282. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 283. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 289. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 290. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 291. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 296. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 297. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 298. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 299. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 304. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 305. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 306. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 307.